Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin, Harvard Form Strategic Research Alliance
March 1, 2021
- Daiichi Sankyo to Divest 11 Off-Patent Brands to Alfresa
March 1, 2021
- Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
- UCB Files Psoriasis Med Bimekizumab for Japan Approval
March 1, 2021
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
- Taiho’s HSP90 Inhibitor Extends PFS in GIST
February 24, 2021
- Lusefi’s OD Film Version Filed in Japan: Taisho
February 24, 2021
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Chugai to Develop Atea’s COVID-19 Drug AT-527 in Japan
February 22, 2021
- Japan-Bound Flights for COVID-19 Vaccines Get Underway: Pfizer, DHL, ANA
February 22, 2021
- Mitsubishi Tanabe, Keio University Tie Up for Research of Neutralizing Antibodies for COVID-19
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Kyowa Kirin’s Novel Antibody Hits Primary Goal in Global PII for Atopic Dermatitis
February 19, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…